TITLE

Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia

AUTHOR(S)
Elefante, Anjana; Czuczman, Myron S.
PUB. DATE
May 2010
SOURCE
American Journal of Health-System Pharmacy;5/1/2010, Vol. 67 Issue 9, p713
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The pharmacology, efficacy, safety, and dosage and administration of bendamustine and its use in indolent non- Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are reviewed. Summary. Bendamustine is an alkylating agent that has a unique, multifaceted mechanism of action. Compared with other alkylators, bendamustine produces moreextensive and long-lasting DNA damage. Bendamustine also inhibits cell-cycle checkpoints, leading to mitotic catastrophe and apoptosis. Bendamustine is approved for the treatment of CLL and for indolent B-cell NHL that has progressed during or within 6 months of treatment with rituximab or a rituximab-based regimen. In Phase II and III trials in patients with indolent NHL and CLL, bendamustine has demonstrated response rates of 67-84% as a single agent and median durations of response of 7-21 months. Additional clinical trials are examining bendamustine as a single agent and in combination therapy for the treatment of hematologic malignancies and solid tumors. Adverse events associated with bendamustine are typically mild to moderate and can usually be managed with supportive care. Myelosuppression is the most common grade 3 or 4 adverse event. Tumor lysis syndrome has been reported to occur in some patients, and preventive measures should be taken in at-risk patients. The dosage and administration differ for the treatment of NHL and CLL. Conclusion. Bendamustine is a welltolerated and effective chemotherapeutic agent indicated for the treatment of rituximab-refractory, indolent NHL and CLL. It has demonstrated efficacy in patients whose disease is refractory to other therapies, including other alkylating agents.
ACCESSION #
49443183

 

Related Articles

  • Chlorambucil.  // AHFS Consumer Medication Information;Jan2017, p1 

    Chlorambucil is used treat a certain type of chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Chlorambucil is also used to treat non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (types of cancer that begin in certain white blood cells that normally fight...

  • Stability-Indicating High Performance Liquid Chromatographic Determination of Bendamustine Hydrochloride (An Anti-Cancer Agent) as Bulk Drug and in Pharmaceutical Dosage Form. Annapurna, M. Mathrusri; Kumar, B. Sai Pavan; Prakash, J. Raj // Drug Invention Today;Dec2012, Vol. 4 Issue 12, p629 

    Bendamustine hydrochloride is an alkylating agent used for the treatment of chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma and lung cancer. A selective, specific and sensitive stability-Bendamustine hydrochloride indicating high-performance liquid...

  • A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Van der Jagt, R.; Laneuville, P.; MacDonald, D.; Stewart, D.; Christofides, A.; Sehn, L. H. // Current Oncology;Jun2012, Vol. 19 Issue 3, p160 

    No abstract available.

  • Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. Plosker, Greg L.; Figgitt, David P. // Drugs;2003, Vol. 63 Issue 8, p803 

    Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL). While the optimal use of the drug in many...

  • A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Tefferi, A; Li, C-Y; Reeder, C B; Geyer, S M; Allmer, C; Levitt, R; Michalak, J C; Addo, F; Krook, J E; Witzig, T E; Schaefer, P L; Mailliard, J A // Leukemia (08876924);Aug2001, Vol. 15 Issue 8, p1171 

    In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and 2-chlorodeoxyadenosine and reported overall (OR) and complete (CR) remission rates of 80% and 20%, respectively. After a median follow-up of 5...

  • Bendamustine Injection.  // AHFS Consumer Medication Information;Jan2017, p1 

    Bendamustine injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Bendamustine injection is also used to treat a type of non-Hodgkins lymphoma (NHL: cancer that begins in a type of white blood cell that normally fights infection) that is slow...

  • Bendamustine: A Review of its Use in the Management of Indolent Non-Hodgkin Lymphoma. Plosker, Greg L.; Carter, Natalie J. // Drugs;2008, Vol. 68 Issue 18, p2645 

    Abstract Bendamustine (Treanda®, Ribomustin®) is a bifunctional alkylating agent that also has potential antimetabolite properties, and only partial cross-resistance occurs between bendamustine and other alkylators. In patients with indolent non- Hodgkin lymphoma (NHL), bendamustine...

  • New Therapies for Patients with Chronic Lymphocytic Leukemia. Robak, Tadeusz; Robak, Pawel // Current Cancer Therapy Reviews;2008, Vol. 4 Issue 4, p235 

    For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb)....

  • TOP STORIES OF 2008.  // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p8 

    This section offers medical news briefs. According to the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, recombinant activated Factor VIIa, a prohaemostatic agent, reduced the growth of hematoma, but did not improve the survival or functional outcome after stroke-related intracerebral...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics